NeoGenomics Q3 2026 slides: 53% EBITDA growth drives guidance raise
NeoGenomics Inc. (NASDAQ:NEO) reported Q3 2026 revenue of $209M (up 11% YoY) and adjusted EBITDA of $19M (up 53% YoY), raising full-year guidance. Clinical revenue grew 13% YoY, driven by NGS tests. The company announced leadership changes and secured MolDX reimbursement for IO monitoring. Shares closed at $17.99, up 4.17%.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to attract new buying interest, while the leadership change adds a neutral factor.
Market read
First‑report earnings with guidance lift; high relevance for traders focused on biotech and healthcare small caps.
What to watch
Potential headwinds from reimbursement policy changes and the $10 M DOJ settlement could temper upside.
Background
NeoGenomics announced a leadership transition and infrastructure upgrades alongside its earnings release.
Ticker impact
NeoGenomics reported Q3 2026 results with 53% adjusted EBITDA growth and raised full-year guidance, a fresh earnings disclosure.
upward pressure as investors price in higher earnings outlook
The earnings beat and guidance lift are new, material information that typically prompts buying interest.
Market effects
Strengthens the precision oncology testing sector, supporting peers with similar NGS exposure.
Positive for US biotech and healthcare stocks, especially small‑cap oncology players.
Limited to the niche oncology diagnostics market; no broad macro impact.
Counterpoint
If the guidance raise is already priced in, the stock may face a short‑term pullback on profit‑taking.
Key entities
- companyNeoGenomics Inc.
NASDAQ‑listed precision oncology testing firm.
- executiveWarren Stone
President and COO promoted to CEO effective Jan 4 2027.
